Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak
- 20 June 2021
- journal article
- research article
- Published by Wiley in Biotechnology Progress
- Vol. 37 (5), e3186
- https://doi.org/10.1002/btpr.3186
Abstract
The global pandemic outbreak COVID-19 (SARS-COV-2), has prompted many pharmaceutical companies to develop vaccines and therapeutic biologics for its prevention and treatment. Most of the therapeutic biologics are common human IgG antibodies, which were identified by next-generation sequencing with the B cells from the convalescent patients. To fight against pandemic outbreaks like COVID-19, biologics development strategies need to be optimized to speed up the timeline. Since the advent of therapeutic biologics, strategies of transfection and cell line selection have been continuously improved for greater productivity and efficiency. Next-generation sequencing (NGS) has also been implemented for accelerated cell bank testing. These recent advances enable us to rethink and reshape the chemistry, manufacturing and controls (CMC) strategy in order to start supplying GMP materials for clinical trials as soon as possible. We elucidated an accelerated CMC workflow for biologics, including using GMP-compliant pool materials for Phase I clinical trials, selecting the final clone with product quality similar to that of Phase I materials for late-stage development and commercial production.Keywords
This publication has 44 references indexed in Scilit:
- Vesivirus 2117: Cell line infectivity range and effectiveness of amplification of a potential adventitious agent in cell culture used for biological productionBiologicals, 2016
- Advanced Virus Detection Technologies Interest Group (AVDTIG): Efforts on High Throughput Sequencing (HTS) for Virus DetectionPDA Journal of Pharmaceutical Science and Technology, 2016
- Advances in recombinant antibody manufacturingApplied Microbiology and Biotechnology, 2016
- Comparison of three transposons for the generation of highly productive recombinant CHO cell pools and cell linesBiotechnology & Bioengineering, 2015
- Detection of Adventitious Agents Using Next-Generation SequencingPDA Journal of Pharmaceutical Science and Technology, 2014
- Defining a Sample Preparation Workflow for Advanced Virus Detection and Understanding Sensitivity by Next-Generation SequencingPDA Journal of Pharmaceutical Science and Technology, 2014
- Development of recombinant Chinese hamster ovary cell lines for therapeutic protein productionCurrent Opinion in Chemical Engineering, 2013
- Fast identification of reliable hosts for targeted cell line development from a limited‐genome screening using combined φC31 integrase and CRE‐Lox technologiesBiotechnology Progress, 2013
- Transgene copy number distribution profiles in recombinant CHO cell lines revealed by single cell analysesBiotechnology & Bioengineering, 2012
- Cell culture processes for monoclonal antibody productionmAbs, 2010